A Phase 1b Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas

Trial Profile

A Phase 1b Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Oxaliplatin; Rituximab
  • Indications B cell lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Acronyms BIBLOS
  • Most Recent Events

    • 06 Dec 2016 Preliminary results (n=25) assessing safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 19 Oct 2015 Planned End Date changed from 1 Dec 2017 to 1 Nov 2019 as reported by ClinicalTrials.gov record.
    • 19 Oct 2015 Planned primary completion date changed from 1 Nov 2016 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top